Table 3

Baseline characteristics and perioperative factors after propensity-score matching based on DMT use

DMT, n = 365No DMT, n = 365P
Demographic variables, n (%)    
 Age ≥75 y 161 (44.1) 161 (44.1) 1.000 
 Female gender 298 (81.6) 291 (79.7) .512 
 Body mass index ≥30 kg/m2 26 (7.1) 37 (10.1) .147 
Preoperative laboratory data, n (%)    
 Red cell count ≥6 × 1012/L (male) or ≥5.5 × 1012/L (female) 0 (0) 0 (0) — 
 Platelet count ≥400 × 109/L or <100 × 109/L 18 (4.9) 16 (4.4) .725 
 White cell count ≥10 × 109/L 14 (3.8) 15 (4.1) .850 
 Serum albumin <3.5g/dL 89 (24.4) 89 (24.4) 1.000 
 e-GFR <60 mL/min/1.73m2 83 (22.7) 82 (22.5) .929 
 Preoperative anti-PF4/heparin antibodies: positive 8 (2.2) 7 (1.9) 1.000 
Medical history, n (%)    
 Hypertension 246 (67.4) 254 (69.6) .524 
 Diabetes mellitus 49 (13.4) 57 (15.6) .401 
 Dyslipidemia 50 (13.7) 51 (14.0) .915 
 Atrial fibrillation 7 (1.9) 9 (2.5) .801 
 Malignancy 22 (6.0) 27 (7.4) .460 
 Rheumatoid arthritis 51 (14.0) 42 (11.5) .318 
 Venous thromboembolism 6 (1.6) 8 (2.2) .604 
Operative variables, n (%)    
 Type of surgery: TKA 235 (64.4) 236 (64.7) .938 
 Operation time ≥120 min 187 (51.2) 199 (54.5) .374 
 Type of anesthesia    
  General 113 (31.0) 103 (28.2) .417 
  Combination of epidural and general 190 (52.1) 192 (52.6) .882 
  Epidural 7 (1.9) 9 (2.5) .801 
  Spinal 55 (15.1) 61 (16.7) .544 
Postoperative thromboprophylaxis, n (%)    
 UFH 19 (5.2) 28 (7.7) .175 
 LMWH 23 (6.3) 41 (11.2) .018 
 Fondaparinux 55 (15.1) 60 (16.4) .611 
 Antiplatelet drug 9 (2.5) 5 (1.4) .419 
 GCSs 353 (96.7) 360 (98.6) .139 
DMT, n = 365No DMT, n = 365P
Demographic variables, n (%)    
 Age ≥75 y 161 (44.1) 161 (44.1) 1.000 
 Female gender 298 (81.6) 291 (79.7) .512 
 Body mass index ≥30 kg/m2 26 (7.1) 37 (10.1) .147 
Preoperative laboratory data, n (%)    
 Red cell count ≥6 × 1012/L (male) or ≥5.5 × 1012/L (female) 0 (0) 0 (0) — 
 Platelet count ≥400 × 109/L or <100 × 109/L 18 (4.9) 16 (4.4) .725 
 White cell count ≥10 × 109/L 14 (3.8) 15 (4.1) .850 
 Serum albumin <3.5g/dL 89 (24.4) 89 (24.4) 1.000 
 e-GFR <60 mL/min/1.73m2 83 (22.7) 82 (22.5) .929 
 Preoperative anti-PF4/heparin antibodies: positive 8 (2.2) 7 (1.9) 1.000 
Medical history, n (%)    
 Hypertension 246 (67.4) 254 (69.6) .524 
 Diabetes mellitus 49 (13.4) 57 (15.6) .401 
 Dyslipidemia 50 (13.7) 51 (14.0) .915 
 Atrial fibrillation 7 (1.9) 9 (2.5) .801 
 Malignancy 22 (6.0) 27 (7.4) .460 
 Rheumatoid arthritis 51 (14.0) 42 (11.5) .318 
 Venous thromboembolism 6 (1.6) 8 (2.2) .604 
Operative variables, n (%)    
 Type of surgery: TKA 235 (64.4) 236 (64.7) .938 
 Operation time ≥120 min 187 (51.2) 199 (54.5) .374 
 Type of anesthesia    
  General 113 (31.0) 103 (28.2) .417 
  Combination of epidural and general 190 (52.1) 192 (52.6) .882 
  Epidural 7 (1.9) 9 (2.5) .801 
  Spinal 55 (15.1) 61 (16.7) .544 
Postoperative thromboprophylaxis, n (%)    
 UFH 19 (5.2) 28 (7.7) .175 
 LMWH 23 (6.3) 41 (11.2) .018 
 Fondaparinux 55 (15.1) 60 (16.4) .611 
 Antiplatelet drug 9 (2.5) 5 (1.4) .419 
 GCSs 353 (96.7) 360 (98.6) .139 

This table shows the differences in baseline characteristics and perioperative factors between 365 pairs of patients based on use of DMT (intermittent plantar compression device [foot pump] or IPCD) after propensity-score matching on a 1:1 basis.

Close Modal

or Create an Account

Close Modal
Close Modal